Abstract:Objective To investigate the effects of Lysine, Inositol and Vitamin B12 Oral Solution, vitamin D3 combined with recombinant human growth hormone (rhGH) on bone mineral density and the levels of 25-hydroxyvitamin D [25 (OH) D], insulin growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in children with dwarfism.Methods A total of 104 children with dwarfism who were treated in our hospital from January 2020 to September 2021 were selected, and they were randomly divided into observation group (n = 52) and control group (n = 52) by the envelope method. The observation group was treated with Lysine, Inositol and Vitamin B12 Oral Solution, vitamin D3 combined with rhGH, while the control group was treated with only rhGH. The therapeutic efficacy and the changes of the serum levels of 25 (OH) D, IGF-1, and IGFBP-3 before and after the treatment in the two groups were observed.Results The differences of height, weight, growth rate, bone mineral density, bone age, and serum levels of osteocalcin (OC), bone alkaline phosphatase (BALP), procollagen type I N-terminal propeptide (PⅠNP), 25 (OH) D, IGF-1, and IGFBP-3 before and after the treatment in the observation group were significantly higher than those in the control group (P < 0.05).Conclusions The combination of Lysine, Inositol and Vitamin B12 Oral Solution, vitamin D3 and rhGH shows great therapeutic efficacy for dwarfism. It not only improves the bone mineral density and bone metabolism, but also elevates the serum levels of 25 (OH) D, IGF-1, and IGFBP-3 in the children.